NewTimeSpace News: HENLIUS (02696.HK) announced on 10 July that the Phase I clinical trial application for self-developed HLX37 (recombinant humanized anti-PD-L1/anti-VEGF bispecific antibody injection) in combination with chemotherapy or HLX43 for injection (PD-L1 targeted ADC) for advanced/metastatic solid tumours has been approved by NMPA. No similar combination regimen has been approved globally to date. The Company cautions there is no guarantee of successful development and commercialisation.
NewTimeSpace News: HENGRUI PHARMA (01276.HK) announced on 10 July that it has received a Complete Response Letter (CRL) from the US FDA regarding the BLA for camrelizumab for injection combined with apatinib as first-line treatment of unresectable or metastatic hepatocellular carcinoma. The feedback mainly concerns cGMP inspection observations at the apatinib manufacturing site and does not involve clinical data, safety or efficacy issues. Final analysis of the CARES-310 trial demonstrated median overall survival of 23.8 months, the longest median OS reported for first-line liver cancer treatment to date. The Group will communicate actively with the FDA and partner Elevar Therapeutics to clarify next submission plans, while noting there is uncertainty over approval.
NewTimeSpace News: On 10 July 2026, RoboSense (02498.HK) trended upward in the afternoon session. As of 15:24, the stock traded at HK$23.50, representing a 0.17% gain. The Company’s total LiDAR shipments reached 388,900 units in the second quarter of 2026.
NewTimeSpace (newtimespace.com) reported that on July 10, 2026, semiconductor‑related themes continued to rise, with HUA HONG GRACE (01347.HK) extending its upward momentum. As of 13:36, the stock was quoted at HKD 208.800, up 3.47%.
NewTimeSpace News: LEADS BIOLABS-B (09887.HK) announced that the Biologics License Application (BLA) for VELIXIN™ (Opamtistomig, LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy for advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) has been accepted into the Priority Review procedure by CDE under NMPA. The review timeline is shortened from the standard 200 working days to 130 working days. VELIXIN™ is the world’s first 4-1BB-targeted bispecific antibody entering single-arm pivotal clinical stage. The Company reminds investors there is no guarantee of successful development or commercial launch.
NewTimeSpace (newtimespace.com) reported that on July 10, 2026, the humanoid robot theme rallied sharply, with Midea Group (00300.HK) fluctuating slightly higher. As of 13:17, the stock was quoted at HKD 88.800, up 0.40%.
NewTimeSpace News: SDHS NEW ENERGY (01250.HK) announced that Fitch Sustainable affirmed its ESG entity rating at Tier 2 (Tier 1 represents the highest standard) with an entity score of 80, representing an increase of 2 points versus 2025. Scope 3 emissions data were disclosed for the first time in this year’s ESG Report and Climate Action Whitepaper, and an internal carbon pricing mechanism has been established.
NewTimeSpace News: SSY GROUP (02005.HK) announced that a total of 95 varieties (141 specifications) of the Group’s products have been incorporated into the National Essential Medicines List (2026 Edition), including 32 newly added varieties (37 specifications). The catalogue will take effect on 1 September 2026 and is expected to exert a positive impact on the Group’s growth and business development.
NewTimeSpace News: IMMUNEONCO-B (01541.HK) announced on 10 July that first patient dosing has been completed in the Phase II/III clinical trial of self-developed IMM0306 for IgG4-related disease (IgG4-RD). IMM0306 is the world’s first CD47/CD20 bispecific molecule to enter clinical development. The Company owns global intellectual property and commercialisation rights for IMM0306, while cautioning there is no guarantee of successful development or eventual launch.
NewTimeSpace News: Befar Group (06745.HK) commenced trading on HKEX today. The final offer price was fixed at HK$3.48. As at press time, the stock traded at HK$2.73, down HK$0.75 or 21.55% against the final offer price.
NewTimeSpace News: NEXCHIP (02249.HK) commenced trading on HKEX today. The stock opened at HK$36, representing a rise of HK$3.7 or over 11% compared with the offering price of HK$32.3.
NewTimeSpace (newtimespace.com) News, MINIMAX-W (00100.HK) plans to issue in total 35.6 million shares by placement, with estimated net proceeds of HKD 9.49 billion.
NewTimeSpace (newtimespace.com) News, HK ENT INTL (08291.HK) plans to conduct a rights issue on the basis of \\"1 for 3\\", with estimated net proceeds of HKD 30.7 million.
NewTimeSpace (newtimespace.com) News, QUANTGROUP (02685.HK) plans to issue in total 4.6 million shares by subscription, with estimated net proceeds of HKD 59.7 million.
NewTimeSpace News: CREATIVE CHINA (08368.HK) plans to issue in total 114.42 million shares.
NewTimeSpace News: GEEKPLUS-W(02590.HK) will spend HKD 9.53 million to repurchase 900 thousand shares on Jul 9, 2026.
